Company intelligence / Profile preview
Shanghai YaKe Biotechnology
Shanghai, Shanghai, Chinayakebiotech.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai YaKe Biotechnology is a leading Chinese biotech focused on developing innovative cancer immunotherapies using proprietary CAR-T cell technology. The company has advanced multiple autologous and allogeneic CAR-T therapies into Phase 2 trials targeting hematological cancers such as ALL, multiple myeloma, CLL/NHL. Its pipeline includes single-targeted and dual-targeted constructs against antigens like CD19, BCMA, GPRC5D, CD22/CD19 combo. Early data show promising efficacy in relapsed/refractory blood cancers.
- Therapeutic areas
- Rare DiseasesHematologyOncologyImmunologyRheumatology
- Modalities
- CAR-T cell therapyGene therapyHematopoietic stem cell therapy
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Zhejiang University
Beyond the preview
Go deeper on Shanghai YaKe Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai YaKe Biotechnology.